Tenomix Inc

At Tenomix, we’re fighting cancer by pioneering a new class of automated, ultrasound-guided robotic tissue analysis platform. We integrate AI, robotics, and ultrasound imaging into a single system that transforms how excised tissues are analyzed, starting with one of the most time-consuming and inconsistent steps in the cancer staging workflow: lymph node retrieval. Today, this 100-year-old manual process creates bottlenecks, missed nodes, and significant variability across hospital labs. Tenomix automates the tissue interrogation workflow, helping teams work faster, more consistently, and with greater confidence. Our platform generates rich, structured ex vivo datasets (the kind that have never been captured before), unlocking new diagnostic possibilities and allowing teams to use their time and expertise where it matters most. Where automation meets tissue intelligence, a new era of precision oncology begins. Beyond our first application in colorectal cancer, we’re building a scalable, adaptable platform that supports future diagnostic tools, integrates with in vivo imaging insights, and aligns with the evolving needs of high-throughput cancer centers. Founded in 2021 by four innovators with deep clinical, engineering, and personal ties to cancer, Tenomix is backed by leading investors and collaborates closely with top-tier hospital institutions. Our mission is simple: empower pathology teams, modernize a critical part of cancer care, and unlock a future where tissue intelligence improves outcomes for every patient.